Gossamer's CR3 agonist sensitizes pancreatic cancer to therapies

INDICATION: Pancreatic cancer

Gossamer Bio Inc.'s CR3 agonist, GB1275, could sensitize pancreatic cancer to chemotherapy, radiation and immunotherapy. A team co-led by Rush University's Vineet Gupta, who co-founded Gossamer-acquired Adhaere Pharmaceuticals Inc., showed that GB1275 -- formerly ADH-503 -- plus gemcitabine and paclitaxel resulted in the formation of no hepatic metastases, reduced tumor size by >90% in mice with pancreatic cancer and extended survival of all mice beyond 50 days. The chemotherapy combo alone led to hepatic metastases in 55% of the mice, a 35% reduction in tumor size and no survivors at 50 days. GB1275 also increased response to radiation and IgGs against PD-1 and 4-1BB in mice with the disease. Gossamer plans to start Phase I/II testing of GB1275 for solid tumors this half...